metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)
versus sorafenib
	atezolizumab plus bevacizumab
	IMbrave-150, 2020 N. Engl. J. Med. 2020; 382:1894-1905 The Lancet Oncology J Hepatol 2022; 76:862-873-. NCT03434379	RCT	mHCC - 1st line (L1)	atezolizumab-bevacizumab	sorafenib	patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment	336 / 165	some concern	conclusif	demonstrated 42 % decrease in deaths (OS) (PE) demonstrated 41 % decrease in progression or deaths (PFS) (PE) demonstrated 1.8-fold increase in objective responses (ORR) (PE)
	nivolumab alone
	CheckMate 459, 2019 Annals of Oncology 2019 Lancet Oncol 2022 Jan;23(1):77-90. NCT02576509	RCT	mHCC - 1st line (L1)	nivolumab	sorafenib	first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) / patients (at least 18yr) with hiistologically confirmed advanced hepatocellular carcinoma ot eligible for, or whose disease had progressed after, surgical or locoregional therapies	371 / 372	some concern	suggested	inconclusive 15 % decrease in deaths (OS) (PE)
mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)
versus placebo
	pembrolizumab alone
	KEYNOTE-240, 2020 J. Clin. Oncol. 2020; 38:193-202 Cancer 2020 Nov 24. Liver Cancer 2021 Jun;10(3):275-284. NCT02702401	RCT	mHCC - 2nd line (L2)	pembrolizumab	placebo	previously treated patients with advanced hepatocellular carcinoma (HCC)	278 / 135	low	inconclusive	suggested 22 % decrease in deaths (OS),deaths (OS) (PE) suggested 28 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE)
	pembrolizumab based treatment
	KEYNOTE-394, 2022 NCT03062358	RCT	hepatocell cancer (HCC), mHCC - 2nd line (L2)	pembrolizumab	placebo	Asian participants with previously systemically treated advanced hepatocellular carcinoma (HCC)	300 / 153	NA	conclusif	demonstrated 21 % decrease in deaths (OS),deaths (OS) (PE) demonstrated 26 % decrease in progression or deaths (PFS),progression or deaths (PFS) (PE)